Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make
- Details
- Published on Sunday, 29 November -0001 16:00
- Written by editor
MOST READ
Merck Sells Federally Financed Covid Pill to U.S. for 40 Times What It Costs to Make
Sharon Lerner
The Covid-19 treatment molnupiravir was developed using funding from the National Institutes of Health and the Department of Defense.
The CIA’s Afghan Proxies, Accused of War Crimes, Will Get a Fresh Start in the U.S.
Andrew Quilty, Matthew Cole
The agency prioritized the evacuation of Zero unit members and their families even as many vulnerable U.S. employees and human rights activists were left behind.
Protecting freedom of the press has never been more important. Be the next person to support The Intercept’s independent journalism by becoming a member today.
Top Stories
We Can Shut Down the Crimes Exposed by the Pandora Papers — If We Want
Jon Schwarz
Crushing the tax haven racket is a big political challenge, but the steps needed are straightforward and simple.
How the U.S. Derailed an Effort to Prosecute Its Crimes in Afghanistan
Alice Speri
The International Criminal Court’s decision to “deprioritize” a probe into crimes by the U.S. and its allies came after years of U.S. obstruction.
The U.S. Is Organizing a $5 Million Gun Sale to Mexican Forces Accused of Murder and Kidnapping
Ryan Devereaux
As the two countries meet this week to discuss security cooperation, lawmakers see the sale as evidence of a systemic problem.
How Much Is $3.5 Trillion, Really?
Jon Schwarz, Travis Mannon
The proposed $3.5 trillion for the Build Back Better agenda is much, much less money than you think — but don’t expect the corporate media to tell you that.
Podcasts
The Quest for Covid’s Origins
Intercepted
Recent reporting by The Intercept demonstrates a lack of transparency in the search for the origins of Covid-19.
First Look Institute is a 501(c)(3) charitable organization (tax ID number 80-0951255).
The Intercept’s mailing address is:
First Look Institute
P.O. Box 27442
Washington, DC 20038
The Intercept is an award-winning nonprofit news organization dedicated to holding the powerful accountable through fearless, adversarial journalism. Our in-depth investigations and unflinching analysis focus on surveillance, war, corruption, the environment, technology, criminal justice, the media and more. Email is an important way for us to communicate with The Intercept's readers, but if you'd like to stop hearing from us, click here to unsubscribe or update your subscription preferences.
Become a member of The Intercept today and support our independent journalism.
